SafeBeing User vs QoG

SafeBeing is a passive and remote monitoring platform powered by Somatix that is used to monitor ADLs (Activities of Daily Living), such as activity level, mobility, drinking, falls, and medication intake, enabling immediate intervention and identification of irregularities from the user’s normal routine. The mobile app provides both daily and aggregate statistics of the user’s activities, and is used to connect to the Somatix smartband or other compatible smartwatch via Bluetooth (BLE), which is needed for monitoring. The onboarding process is simple and secure, allowing the user to register on the app after being registered into the SafeBeing system by the facility, clinic, or other organization responsible for monitoring the user’s activities. Alerts and notifications are customizable, such as enabling and muting alerts, sharing location, etc. Activity information and alerts can be optionally sent to caregivers or family members via the SafeBeing Caretaker mobile app, including alerts about falls or wandering outside of a designated safe zone. Disclaimer: This app is intended write for personal tracking, awareness, and general wellness purposes only, but it is not a not intended to be medical advice, diagnosis, or treatment. Always consult with a qualified healthcare provider before making any medical decisions or starting, stopping, or modifying any treatment based on information provided by this app. Never disregard professional medical advice or delay seeking it because of something you have read or accessed through this app. Jurisdiction Disclaimer This app supports syncing with select third-party devices that are cleared by both the U.S. Food and Drug Administration (FDA) and the European Union Medical Device Regulation (EU MDR). Exception: The Roche Accu-Chek Guide blood glucose meter is FDA-cleared only and does not have EU MDR clearance. As a result, this device is not authorized for use with this app in the European Union or other regions requiring MDR compliance.

Quit on the Go is a digital therapeutic for smoking cessation only available to participants of a clinical trial conducted at Duke University.